EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 143 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Sacituzumab Govitecan Plus Pembrolizumab Prolongs PFS Among Patients with Previously Untreated, PD-L1-positive, Advanced TNBC FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma MOST POPULAR Lack of Benefit of Adding Immune Checkpoint Inhibitors to Chemotherapy in... December 6, 2021 Cancer Mortality Prediction for 2025 Continues to Show Favourable Trends In... April 16, 2025 Catch-Up HPV Testing May Help Prevent Cervical Cancer in Some Over... September 1, 2023 Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs June 25, 2020 Load more HOT NEWS Reflections from the World Cancer Congress Tomorrow is National Prescription Drug Take-Back Day! FDA Approves Abatacept for Prophylaxis of Acute Graft Versus Host Disease Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors
